Dr Steven Whittaker left the ICR in October 2019. His team used in vitro techniques and genome screening to identify genetic mutations that either promote resistance or induce sensitivity to a particular drug.
Dr Whittaker and colleagues identified novel therapeutic strategies to overcome clinically relevant mechanisms of resistance to BRAF inhibitors. On his return to the ICR as a Career Development Fellow in 2013, Dr Whittaker established a new effort to advance our knowledge of drug resistance mechanisms, to identify new drug targets and generate novel therapeutic strategies for the treatment of cancer. Dr Whittaker left the ICR in October 2019.